A Mendelian randomization study [PMID: 36045366] Laboratory literature summary: L-carnitine, a friend or foe for cardiovascular disease
People who experience vulvovaginal changes while taking a GLP-1 may notice the following: loss of volume and plumpness in the labia majora and mons pubis (the fat that sits on the pubic bone) sagging or wrinkled skin changes in the shape of the vulva If a person is experiencing hormonal changes associated with perimenopause and menopause, they may also experience: dryness and itching burning and irritation thinner, more fragile vaginal tissues, which can tear more easily pain during intercourse The primary cause of a saggy vulva after using a GLP-1 is rapid fat loss
GLP-1RA promotes the secretion of GLP-1 by intestinal L cells while inhibiting the secretion of glucagon by alpha cells, forming a positive feedback regulation of the "gut pancreas" axis
Patients lead the way The most important driver in the boom of Mounjaro and GLP-1s has undeniably been patient demand
Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations to Optimal Translation
Thus, L-type VDCCs played a minor role as mediators of sustained Ca 2+ influx stimulated by JWU-A021